Nutriband (US:NTRB) Globenewswireยท2025-06-02 12:00Core Insights - Nutriband Inc. reported a record revenue of $667,000 for Q1 2025, reflecting a 63% year-over-year increase [2] - The company is expanding its kinesiology tape production through its Pocono Pharma subsidiary, focusing on penetration pricing to establish partnerships with major retail brands [2] - Nutriband is advancing the development of AVERSA Fentanyl through a partnership with Kindeva Drug Delivery, aimed at regulatory approval and commercialization [3] Financial Performance - The first quarter revenue of $667,000 represents a significant growth of 63% compared to the same period last year [2] - The increasing revenue from Pocono is crucial for enhancing shareholder value [2] Product Development - AVERSA Fentanyl is being developed as the world's first abuse-deterrent opioid patch, which aims to reduce the risk of misuse and accidental exposure [4] - The potential peak annual sales for AVERSA Fentanyl in the U.S. are estimated to be between $80 million and $200 million [4] - The partnership with Kindeva Drug Delivery involves shared development costs and milestone payments, facilitating the advancement of Nutriband's transdermal drug delivery solutions [3]